Mackay Shields LLC’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-45,855
Closed -$1.91M 964
2021
Q1
$1.91M Sell
45,855
-31,723
-41% -$1.45M 0.01% 789
2020
Q4
$3.31M Sell
77,578
-11,700
-13% -$421K 0.02% 627
2020
Q3
$2.35M Sell
89,278
-24,600
-22% -$685K 0.02% 720
2020
Q2
$3.05M Buy
113,878
+3,500
+3% +$79K 0.02% 577
2020
Q1
$1.99M Sell
110,378
-15,700
-12% -$298K 0.02% 669
2019
Q4
$2.24M Sell
126,078
-30,300
-19% -$525K 0.02% 827
2019
Q3
$2.42M Sell
156,378
-26,400
-14% -$435K 0.01% 824
2019
Q2
$3.14M Buy
182,778
+128,423
+236% +$2.07M 0.02% 735
2019
Q1
$875K Buy
54,355
+2,700
+5% +$43.7K 0.01% 1040
2018
Q4
$756K Sell
51,655
-13,208
-20% -$211K 0.01% 1021
2018
Q3
$1.18M Buy
64,863
+21,200
+49% +$371K 0.01% 838
2018
Q2
$737K Sell
43,663
-1,200
-3% -$22.7K 0.01% 1025
2018
Q1
$879K Buy
+44,863
New +$869K 0.01% 1006

Other funds holding HALO

Mackay Shields LLC's HALO Position: Q2 2021 in Review

Mackay Shields LLC sold out of Halozyme (HALO) in Q2 2021, closing a stake of 45,855 shares — an estimated $1.91M sold.

Mackay Shields LLC first reported a position in HALO in Q1 2018 and held it in 13 quarters. The position peaked at $3.31M in Q4 2020. 313 funds tracked by Wall St. Rank hold HALO as of Q2 2021.

  • Mackay Shields LLC reported no remaining Halozyme position as of Q2 2021 after selling out during the quarter.
  • Mackay Shields LLC sold 45,855 Halozyme shares in Q2 2021, an estimated $1.91M.
  • Mackay Shields LLC first reported a position in Halozyme in Q1 2018 and held it in 13 quarters.
  • Mackay Shields LLC's Halozyme position peaked at $3.31M in Q4 2020.
  • 313 funds tracked by Wall St. Rank held Halozyme as of Q2 2021.

Based on Mackay Shields LLC's 13F filing for Q2 2021, filed 13 Aug 2021.